ClinicalTrials.gg
CompletedNCT02185014Updated Nov 14, 2018Results posted

Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115

A Phase 3 interventional study of Adalimumab in Crohn's Disease, sponsored by AbbVie. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
252
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 42 studies testing adalimumab in Crohn Disease — 4 open to participants now, 5 under way, none of them phase 3. Adalimumab · Crohn Disease.

Enrollment
10th of 42
252 · median 143
Started
2014
with 3 others
Phase 3
22 of 42
none open now
Registered
28th of 42
by date
Lead sponsor
6 of 42
AbbVie

Among the 42 studies testing adalimumab in Crohn Disease, this one is the 10th largest by enrollment, is one of 4 that started in 2014, is one of 22 in phase 3, and was the 28th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

4 of the 42 studies testing adalimumab in Crohn Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies testing adalimumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long term efficacy, safety, and tolerability of repeated administration of adalimumab in participants with Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject successfully enrolled in and completed Study M14-115 (NCT02185014), including the Week 12 ileocolonoscopy.

Exclusion criteria

Exclusion Criteria:

  • If the Week 12 (Study M14-115; NCT02185014) colonoscopy shows evidence of dysplasia or .
  • Subject is not in compliance with prior and concomitant medication requirements throughout M14-115 (NCT02185014).
  • Subject who developed active Tuberculosis (TB) during M14-115 (NCT02185014), or subject who is non compliant with prophylaxis for latent tuberculosis (TB) initiated per M14-115 (NCT02185014) procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
252 participants (actual)

Study arms

  • Other
    Adalimumab

    Participants received open-label adalimumab 40 mg by subcutaneous injection every other week for 40 weeks.

    Drug: Adalimumab

Interventions

  • Adalimumab pre-filled syringe, administered by subcutaneous injection

    Also known as: Humira, ABT-D2E7

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0

    Endoscopic improvement defined as a simple endoscopic score for Crohn's Disease (SES-CD) score of ≤4 and at least a 2-point reduction compared with Study M14-115 (NCT02185014) Baseline and no subscore greater than 1 in any individual endoscopic variable. The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The Total Score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 40

07

Results

Posted Nov 14, 2018

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started252
Completed198
Not completed54
Withdrew: Adverse event18
Withdrew: Withdrew consent8
Withdrew: Lost to follow-up4
Withdrew: Lack of efficacy14
Withdrew: Requires alternative/prohibited therapy5
Withdrew: Subject noncompliance1
Withdrew: Other4

Outcome measures

PrimaryPercentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0

Endoscopic improvement defined as a simple endoscopic score for Crohn's Disease (SES-CD) score of ≤4 and at least a 2-point reduction compared with Study M14-115 (NCT02185014) Baseline and no subscore greater than 1 in any individual endoscopic variable. The SES-CD evaluates 4 endoscopic variables (ulcer size ranging from 0 \[none\] to 3 \[very large\]; ulcerated surface ranging from 0 \[none\] to 3 \[\>30%\]; affected surface ranging from 0 \[none\] to 3 \[\>75%\], and narrowing ranging from 0 \[none\] to 3 \[cannot be passed\]) in 5 segments assessed during ileocolonoscopy (ileum, right colon, transverse colon, sigmoid and left colon, and rectum). The Total Score is the sum of the 4 endoscopic variable scores and range from 0 to 56, where higher scores indicate more severe disease. Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 40
Reported as:
Number · percentage of participants
Percentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 0
percentage of participantsAdalimumab
Percentage of Participants With Endoscopic Improvement at Week 40 in Participants With Endoscopic Improvement at Week 031.6 (21.1 to 42.0)

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 48 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab0/252 (0%)27/252 (10.7%)63/252 (25%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventAdalimumab
CROHN'S DISEASEGastrointestinal disorders14/252
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders4/252
INTESTINAL OBSTRUCTIONGastrointestinal disorders3/252
ANAL ABSCESSInfections and infestations3/252
ABDOMINAL PAIN UPPERGastrointestinal disorders1/252
ILEAL STENOSISGastrointestinal disorders1/252
NON-CARDIAC CHEST PAINGeneral disorders1/252
POST PROCEDURAL HAEMORRHAGEInjury, poisoning and procedural complications1/252
INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders1/252
HEADACHENervous system disorders1/252
Most frequent other events
Most frequent other events
EventAdalimumab
CROHN'S DISEASEGastrointestinal disorders30/252
ARTHRALGIAMusculoskeletal and connective tissue disorders18/252
NAUSEAGastrointestinal disorders15/252
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations13/252

Baseline characteristics

Baseline characteristics from lead-in study M14-115 (NCT02185014)

Age, Continuous
Age, Continuous(years)Adalimumab
Mean37.5 ± 12.71
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female139
Male113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adalimumab
Hispanic or Latino7
Not Hispanic or Latino0
Unknown or Not Reported245
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adalimumab
American Indian or Alaska Native0
Asian10
Native Hawaiian or Other Pacific Islander0
Black or African American12
White229
More than one race1
Unknown or Not Reported0
Simplified endoscopic score for crohn's disease (SES-CD)
Simplified endoscopic score for crohn's disease (SES-CD)(units on a scale)Adalimumab
Mean14.2 ± 6.74
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Nov 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2014
First posted
Jul 9, 2014
Start
Aug 12, 2014
Primary completionActual
Nov 3, 2017
CompletionActual
Nov 3, 2017
Results first posted
Nov 14, 2018
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02185014
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 9, 2014
Start date
Aug 12, 2014
Primary completion
Nov 3, 2017
Completion
Nov 3, 2017
Results posted
Nov 14, 2018
Last update
Nov 14, 2018

Study contacts

AbbVie Inc
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion